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Multiple Sclerosis : the upward trajectory continues 
 
 
The rate and range of publications in multiple sclerosis (MS) continues apace 
reflecting the on-going developments in the field with new treatments, not only for 
relapsing remitting, but more recently positive phase III trials in both primary and 
secondary progressive MS. Selecting only five papers from the last year that improve 
our understanding, provide new insights, or raise awareness is thus a major 
challenge.   
The concept of clinically isolated syndrome is now very well established and the MS 
community is grappling with appropriate characterisation of patients with no clinical 
symptoms, but who are found to have abnormalities on MRI that are consistent with 
those seen in MS - so called radiologically-isolated syndromes (RIS). An elegantly 
written paper by Kantarci and colleagues followed a large RIS cohort of 453 subjects 
studied in 22 clinical sites. During a 15-year follow-up, 128 evolved to symptomatic 
MS, 15 of whom developed primary progressive MS1 (PPMS), with a median time to 
conversion of 3.5 years, demonstrating that subjects with RIS evolve to PPMS in the 
same frequency as would be expected in general MS populations. The strongest 
predictors of evolution of PPMS included male sex, a more advanced age, and the 
presence of initially asymptomatic spinal cord lesions. Such observations suggest 
that RIS can be considered as pre-symptomatic MS and drive the need to place 
more weight  not only on brain, but also spinal cord MRI findings, even when 
presenting in isolation and will doubtless be considered carefully in the  International 
Diagnostic meeting in Philadelphia. 
One of the key questions in relation to the pathology of MS is how new lesions form 
and whether they can be prevented. In an intriguing paper, Smith and his colleagues, 
guided by the hypothesis that demyelination can occur in the relative absence of 
lymphocytes, and with distinctive characteristics suggestive of a tissue energy deficit, 
explored the potential for inspired oxygen in lipopolysaccharide-induced lesions 
(which are described as pattern III lesions, essentially linked to primary 
oligodendrocyte injury) in the rat spinal cord2. Their serial evaluation showed that 
lesions occurred at the white matter- grey matter border (in the vascular watershed 
area) and were associated with hypoxia, superoxide and nitric oxide formation. 
Furthermore, inspired oxygen reduced demyelination. Whilst these findings, together 
with the safety of oxygenation, including the reversal of ongoing hypoxia, need to be 
verified, they suggest a key role for hypoxia in the pattern III lesions.  
The application of pathologically specific imaging biomarkers is another strategy to 
increase our understanding of underlying disease mechanisms in MS and while MRI 
has proven very valuable in diagnostics and clinical trials, Positron Emission 
Tomography (PET) provides additional scope as has been very beautifully 
demonstrated in Bodini’s study of demyelination and remyelination3. They carried out 
a longitudinal study in 20 MS patients and 8 healthy controls combining PET with a 
specific tracer to explore myelin dynamics - Pittsburgh compound B ([11C]PiB) and 
MRI. They described the dynamics of both demyelination and remyelination and 
computed an index of remyelination, which may reflect the individual remyelination 
potential and inversely correlated with clinical disability. This should encourage 
further application of high-resolution PiB-PET to assess the efficacy of remyelinating 
therapies. 
The acceleration of new treatments for progressive MS, as articulated by the 
Progressive MS Alliance, took a major hit when the important and well- designed, 
trial of fingolimod in primary progressive MS turned out to be negative4. Nonetheless, 
this trial has the potential to tell us much about the mechanisms underlying 
progression and bringing this data together with other trials of primary progressive 
MS will be extremely valuable. Of more promise is the positive trial of phenytoin in 
optic neuritis5. This phase II trial of patients with acute optic neuritis, presenting 
within 2 weeks from onset, was based on the premise that phenytoin is 
neuroprotective through its inhibition of voltage-gated sodium channels. There was a 
positive finding of a 30% reduction in the extent of retinal nerve fibre layer loss in the 
treatment arm. This encouraged the authors to postulate that they may well be 
demonstrating a neuroprotective effect an important therapeutic approach in 
progressive MS.    
Finally, and under the banner of raising the profile of an important but neglected area 
is the series of papers on MS co-morbidities, emanating from a workshop led by 
Ruth Anne Marrie in Toronto in March 2015. A supplement containing six papers 
was produced in Multiple Sclerosis Journal (MSJ) which described the landscape 
prior to the workshop. The meeting resulted in two major outputs which aim to clarify 
the prevalence of key co-morbidities in MS6 and, importantly, determine how they 
should be incorporated into clinical trials both in terms of safety and efficacy of the 
intervention under study7.     
There is a clear sense of advancement in both our understanding and treatment of 
this complex condition, with further developments in progressive MS eagerly 
awaited. 
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